Tag Archives: BioNTech

Why the Pfizer Emergency Use App Decision Isn’t Easy

From insisting on seeking legal protection to waiving clinical trials, Pfizer’s application to the Comptroller General of Drugs of India (DCGI), seeking permission for the Emergency Use Authorization of its COVID-19 vaccine, it has too many buts and yes. The committee of subject matter experts constituted by DCGI is expected …

Read More »